Introduction
In acute lymphoblastic leukemia (ALL), the central nervous system (CNS) may be involved at initial diagnosis and also at relapse. The CNS is considered a sanctuary site due to the limited penetration of cytostatic drugs through the blood-brain barrier into the cerebrospinal fluid (CSF) and the brain parenchyma. In current treatment regimens, the CNS relapse rate was reduced below 5% by a combination of systemic therapy with CNS active drugs such as high-dose (HD) cytarabine or HD methotrexate, intrathecal (IT) therapy and additional CNS irradiation in some trials 1;2 .
In ALL, CNS relapse may occur isolated or in combination with bone marrow (BM) relapse. It can be associated with characteristic symptoms such as headache, nausea, cranial nerve palsies, neurologic dysfunction but be as well detected during a routine lumbar puncture.
CNS relapse is generally confirmed by demonstration of more than 5 blast cells/!l in the cerebrospinal fluid (CSF).
Prospective studies for treatment of CNS relapse in adult ALL are not available. Complete remissions in CNS can be achieved with various treatments including IT therapy with or without additional systemic chemotherapy in 32-94% of the patients [3] [4] [5] [6] [7] . However, despite the generally good response of CNS relapse, the survival of affected adults is extremely poor, with a median of 6 months and a long-term survival probability of 6-8% [3] [4] [5] [6] [7] . Cure is almost exclusively restricted to patients who received allogeneic stem cell transplantation (SCT).
Standard therapy of CNS relapse is based on 2-3 weekly IT injections of methotrexate or a triple combination with methotrexate, cytarabine and steroids until blast clearance, followed by 1-2 additional applications. Frequent lumbar punctures are required and have a significant negative impact on the quality of life of the patients. Cumulative neurotoxicity such as leukoencephalopathy is an important issue in patients with CNS relapse when various CNS active treatments are combined 8;9 . Therefore it is one major aim to achieve complete remission of CNS involvement i.e. cerebrospinal fluid blast clearance with as little cumulative toxicity as possible and to rapidly prepare the patients for SCT.
Liposomal cytarabine is a sustained-release formulation of cytarabine, which is encapsulated in spherical multivesicular particles. After application, free cytarabine is detectable up to 14 days. The prolonged activity allows for an even distribution in the whole lumbar space and cerebral ventricles 10;11 . Previous studies have shown that, when compared with methotrexate (12 mg) or cytarabine (50 mg twice a week), liposomal cytarabine has a similar safety profile and a similar or better effectiveness in the treatment of neoplastic or lymphomatous meningitis respectively 10;12 . Based on the promising efficacy reported from these studies, the European Working Group for Adult ALL (EWALL) has initiated a prospective trial with the aim to demonstrate feasibility and efficacy of liposomal cytarabine in this patient population. The primary endpoint was the CNS response rate after 1-2 cycles. This is to our knowledge the first prospective trial addressing this question.
Design and Methods
We report the results of a prospective non-randomized multicenter and multinational phase II trial. The study was started in April 2004. The study protocol is registered (NCT00199108) and was approved by the ethics committee of the University of Frankfurt, other responsible ethics committees and performed in accordance with the declaration of Helsinki. Written informed consent was obtained from all patients.
Entry criteria
Patients with CNS relapse, isolated or combined with BM relapse in ALL or very aggressive non-Hodgkin's lymphoma (Burkitt/Burkitt-like or B-lymphoblastic NHL) were eligible. Inclusion criteria were: Age " 18 years, Karnofsky index " 60%, absence of uncontrolled infection, recovery from previous grade III/IV toxicities (with the exception of haematotoxicity) and absence of severe heart, lung, liver or kidney dysfunction.
CNS relapse was confirmed either by positive CSF cytology defined as CSF cell counts > 5/!l within 10 days prior to inclusion or by characteristic signs and symptoms in addition to a magnetic resonance imaging or computed tomography (MRI/CT) scan indicating the presence of meningeal or brain involvement. One prior IT treatment of the current CNS relapse was allowed, but the CSF sample taken before the first application of liposomal cytarabine had to confirm CNS involvement.
Study therapy
In all patients, a CSF sample was taken before administration of liposomal cytarabine. The study drug was administered immediately thereafter via lumbar puncture at day 1 and continued with one administration every 14 days for a maximum of 5 additional induction cycles. After demonstration of CSF blast clearance at two time-points within 14 days, monthly injections were scheduled for maintenance ( figure 1 ). The dose of liposomal cytarabine was 50 mg per injection. Liposomal cytarabine was provided by Mundipharma GmbH, Limburg, Germany.
In patients with combined CNS and BM relapse, the invention of systemic therapy was left to the discretion of the physician. However, during induction the use of CNS-active drugs such as HD cytarabine, methotrexate or thiotepa had to be withheld.
In the initial version of the protocol, prophylaxis of arachnoiditis was performed with oral dexamethasone (4 mg bid) for 5 days. On August 10, 2006 the study was amended and the prophylaxis changed to IT dexamethasone (4 mg).
Assessments CSF analysis for cell count and morphology was performed as part of pre-treatment analysis.
All patients had physical and neurological examination. CT/MRI scan or other staging investigations were performed as clinically indicated. BM aspiration was part of the initial study procedures and repeated at restaging if clinically indicated. Restaging assessment of CNS involvement was performed on day 14 (day 28 during maintenance) of each cycle. It included a lumbar puncture with CSF analysis, physical and neurological examination in all patients and additional investigations e.g. CT/MRI scan in patients with brain involvement.
Response Criteria
Complete CNS cytologic response (CNS CR) was defined as conversion from a positive to at least one negative CSF cytology. In patients with initial positive CT/MRI scan, CR was defined as complete resolution of all tumor manifestations in the CT/MRI scan and no progression of neurological symptoms. PR was defined as regression of the tumor manifestations to less than 50%.
Statistical analysis
The major endpoint for efficacy evaluation was best CNS response, defined as any achievement of CNS CR after 1-2 cycles. Toxicity was analyzed as proportion of patients or cycles with adverse events (AEs) according to CTC (Common Toxicity Criteria).
Furthermore, AEs with possible or probable correlation to liposomal cytarabine, as assessed by the investigators, were analyzed separately.
Response and correlation to patient, disease or treatment parameters was analyzed with the #$-test. Time to neurologic disease progression was defined in patients with CNS CR as the time between the first day of study treatment and the day the patient was diagnosed with neurologic progression or the date of last follow-up. Overall survival was calculated from the date of first study drug application to death or to the date of the last follow-up. Survival analysis was performed according to the Kaplan-Meier method. The statistical analysis was peformed in the GMALL study center with the SAS programme (SAS-PC, Version 8; SAS Institute, Cary, NC). For all analyses, p % 0,05 was considered as significant. Eighteen patients had positive CSF cytology. One patient had negative CSF but showed signs of neoplastic meningitis plus a characteristic lesion in the CT scan.
Results

Patient
Sixteen patients (84%) had at least one clinical sign or symptom of neoplastic meningitis on diagnosis, most frequently headache (37%) and cranial nerve abnormalities (42%).
Application of therapy
A median of 4 (1-8) cycles with liposomal cytarabine were administered. Two patients (both Burkitt lymphoma) received only one cycle due to immediate neurologic disease progression, 17 patients had " 2 cycles. Parallel systemic therapy during cycles 1-2 was administered in 4
patients. In 5 patients with Ph-positive ALL, treatment with tyrosine-kinase (TK) inhibitors (3 Dasatinib, 2 Imatinib) was continued. In 6 patients, treatment with liposomal cytarabine was stopped after 4-7 cycles after achievement of CSF CR partly due to adverse events (AE) (5 during maintenance, 1 during induction therapy). Prophylaxis of arachnoiditis with steroids was performed in all patients. 15 patients received oral steroids only (79%), 1 patient IT only and 3 patients both.
Response 14 patients achieved a CNS CR at any time-point. The overall rate of CNS CR (best reponse) was 74%. CNS CR as best response includes 1 patient with a CR after 1 cycle and progression after 2 cycles and 4 patients with first detection of CR after 2 cycles. The CR rate was 86% in B-precursor/T-ALL compared to 40% in Burkitt's lymphoma (table 2) .
One patient with a cerebral lesion showed good response on CT scan after the first cycle with further improvement after the following cycles. Clinical symptoms improved significantly.
At the end of treatment (8 cycles) the patient had achieved a stable partial response for more than 9 months before progression occurred. alive at last follow-up. The median overall survival is 11 (1-31) months. The probability of survival was 45% after 1 year and 18% after 2 years (figure 2b).
Prognostic factors for response
The correlation of CR rate (best response) to potential prognostic factors is shown in table 3.
The difference in terms of CR rate comparing B-precursor-/T-ALL to Burkitt's lymphoma (86% vs. 40%; p=0.05) was significant. There was a trend towards better response in younger compared to patients older than 60 years (82% vs. 63%) and in female compared to male patients (86% vs. 67%). Patients with isolated CNS relapse showed a better response rate compared to patients with combined relapse (82% vs. 62%). Interestingly, patients with previous radiotherapy (prophylactic or for treatment of previous CNS relapse) all achieved CR compared to 55% of patients in the group without previous radiotherapy (100% vs. 55%; p=0.03). However, all of the latter had Burkitt's lymphoma.
Adverse events 19 patients and a total of 82 cycles were evaluable for AE. 17 patients (89%) experienced AE of any degree during at least one cycle. 47 of 82 cycles (57%) were associated with AE.
Further analysis was focussed on grade III-IV AE and on those events with potential correlation to liposomal cytarabine (table 4) .
Grade III/IV events occurred in 24 of 82 cycles (29%) and in 13 out of 19 patients (68%). In 4 patients the AE were associated to progressive disease and/or side effects of systemic dexamethasone therapy. In 3 additional patients the AE were clearly not correlated to liposomal cytarabine. In four patients, leukoencephalopathy was detetected on an MRI scan. In two of these patients, it had already been present on MRI scans prior to study start. In 2 other patients no imaging had been performed before. All of these four patients had Ph-positive ALL with at least 1 (1-4) prior relapse. They all had previously been treated with SCT, TK inhibitors and 3/4 had received cranial irradiation in the past.
Discussion
In adult ALL patients, CNS as well as BM relapse are associated with a poor long-term survival of less than 5% [3] [4] [5] [6] [7] . Although CNS disease generally responds to various treatment approaches, the rate of local or systemic relapse is high and patients are at increased risk to develop neurotoxicity. Quality of life of the patients is affected by frequent IT treatments.
Furthermore, the pharmacological approach of treatment of CNS relapse has to be reconsidered. Methotrexate and cytarabine are cell-cycle specific agents acting particularly in the S-phase. Therefore, prolonged exposure would be required to achieve optimal efficacy, particularly in the CSF where slow proliferation rates of leukemic blasts are expected.
In this setting, liposomal cytarabine has several theoretical advantages. In contrast to methotrexate and cytarabine with half lifes of 3.4 hours and 4.5 hours, liposomal cytarabine yields a half life of 141 hours, although interindividual variability has been described 11;13 .
Promising efficacy data have been reported for lymphomatous meningitis 12 . A prospective study in adult ALL therefore seemed warranted.
Patients included in this trial were heavily pretreated, had a high incidence of unfavourable features and a rather high median age (42% older than 60 years). They thus represented a negatively selected group compared to published studies on CNS relapse of ALL 3-7 with a high proportion of resistant disease and increased risk of toxicities.
The efficacy of treatment with liposomal cytarabine in terms of CNS CR rate was high (74% after 1-2 cycles). Response was significantly better in ALL (86%) compared to Burkitt's lymphoma (40%). It is well known that after relapse the outcome of Burkitt's lymphoma is DOI: 10.3324/haematol.2010.028092 extremely poor. IT therapy was apparently insufficient to control CNS involvement. Additional treatment elements should therefore be considered including systemic therapy, and CNS irradiation in previously non-irradiated patients. Also, IT rituximab is an option. In 7 patients with pediatric B-precursor ALL and refractory CNS relapse, IT rituximab was administered weekly for four consecutive weeks and all of these patients achieved a CR without relevant toxicity 14 .
In the majority of patients in this trial, one application of liposomal cytarabine was sufficient to induce CR. Surprisingly, the drug was also effective in one patient with brain involvement of Burkitt's lymphoma, supporting the observation that liposomal cytarabine is able to diffuse in the brain parenchyma. Patients with Ph-positive ALL needed more cycles to achieve CR but still responded well.
Our results underline the strong single drug effectivity of liposomal cytarabine that appears to be at least equal to the reported response rates of IT triple therapy with or without systemic therapy at 32-94% [3] [4] [5] [6] [7] . Previously, efficacy of liposomal cytarabine has been reported in individual cases or case series with mixed hematologic malignancies. CR rates ranged between 60% and 100% for adult and pediatric ALL [15] [16] [17] , various lymphoma 18 , HIV associated lymphoma 19 , AML 20 or CML myeloid blast crisis 21 . In these retrospective case series, patient populations and treatment were not very well defined. Particularly, treatment with other CNS active drugs was not prohibited and patients with CNS relapse or initial CNS involvement were included.
Overall, liposomal cytarabine was tolerated well. As expected, it was often difficult to differentiate whether AEs were due to CNS involvement, cumulative toxicities of prior therapies, or to acute toxicity of liposomal cytarabine. The large majority of patients (84%) already presented with neurologic signs and symptoms at study entry, which indicates a rather advanced CNS involvement. Grade III-IV toxicities with possible correlation to liposomal cytarabine occurred in 32% of the patients and in 13% of the cycles. Toxicity cumulated in individual patients and appeared to increase with the number of cycles. This underlines the observation that cumulative neurotoxicity is a prominent problem in the treatment of CNS relapse in ALL. To avoid this, treatment with liposomal cytarabine could be shifted earlier in the course of treatment to a monthly maintenance schedule, e.g. after 2
initial applications. It also remains open, whether longer intervals and a limited number of applications in maintenance would be equally effective.
In phase II studies, it has been shown that systemic prophylaxis with dexamethasone can considerably reduce the risk of arachnoiditis and headache 13 . In our trial, two patients suffered from side effects of systemic steroid therapy. This led to the decision to replace oral dexamethasone by IT dexamethasone. The need for steroid co-medication has to be taken into account, if future integration of liposomal cytarabine into CNS prophylaxis is planned.
Chemotherapy of ALL generally includes several cycles of steroids. Here, it may not always be feasible to apply additional systemic steroids as part of CNS prophylaxis. It will be important to develop liposomal cytarabine regimens using less systemic steroids.
Visual disturbances, papilledema and a syndrome resembling optical nerve neuritis were observed in 1 patient in our trial but also by others 22;23 . It is often impossible to distinguish, whether this syndrome is due to subclinical leukemic infiltration of the optical nerve or due to toxicity. It may respond to steroids with complete reconstitution but also to further chemotherapy. Also, several cases of cauda equina or conus medullaris syndrome were reported [23] [24] [25] . This syndrome may as well respond to steroids and be completely reversible. In one study, the respective patients had a history of spinal cord surgery or subarachnoid hemorrhage and the authors speculated that a disturbance of CSF flow may be one possible explanation for increased lumbar toxicity 25 .
Four patients with Ph-positive ALL in our study showed signs of leukoencephalopathy. This is a characteristic result of cumulative neurotoxicity due to a combination of prior CNS irradiation, systemic HD therapy, IT therapy and CNS involvement. In the GMALL trials the risk of leukoencephalopathy was 1% in patients with continuous CR or BM relapse, but significantly higher (11%) in patients with CNS relapse 3 . Despite this knowledge, there is no clinical choice than to treat these patients regardless of their increased risk for leukencephalopathy.
In several studies, liposomal cytarabine was administered in combination with systemic therapy including HD cytarabine 20;26 or HD methotrexate 18 . With frequent applications in combination with the Hyper-CVAD regimen a number of severe neurotoxicities was observed 24 wheras liposomal cytarabine was well tolerated with less frequent applications 27 and no combination with systemic HD cycles 28 .
As expected, the majority of patients who achieved CR relapsed. In pediatric ALL, outcome
of CNS relapse appears to be similarly favourable after intensive chemotherapy and irradiation compared to SCT, with survival rates of 58-71% 29 . In contrast, cure of adult ALL patients after relapse appears only achievable with SCT. Unfortunately, none of our patients could be transferred to SCT. The reason was the high median age excluding a large proportion of patients from SCT. Furthermore, nearly half of the patients already had received a prior allogeneic SCT. Although in younger patients a 2 nd allogeneic SCT is an option, it is generally not considered feasible in older patients and not in all centers.
Nevertheless, a median remission duration of 5 months and a median survival of 11 months was achieved, which should be sufficient to organise and perform SCT in patients amenable to this procedure.
Overall, liposomal cytarabine showed excellent antileukemic activity in CNS relapse of ALL and was well tolerated in the majority of patients. Neurotoxicities were relevant but not unexpected in this heavily pretreated patient population. For improvement of long-term outcome after CNS relapse, a shorter treatment with liposomal cytarabine to bridge into allogeneic SCT in a larger proportion of patients would be important. Furthermore, treatment may be optimized by reduction of the total number of cycles, and intrathecal instead of systemic dexamethasone application.
Liposomal cytarabine is certainly also of interest for prophylaxis of CNS relapse. The advantages are similar as in the relapse situation, e.g. lower frequence of applications.
Prospective trials are ongoing and necessary to define the optimal schedule, frequency and combination with systemic therapy. Particularly the interval between liposomal cytarabine and prior or later systemic HD chemotherapy has to be carefully defined.
It has to be demonstrated whether IT prophylaxis with liposomal cytarabine is as efficient as the triple combination, or whether it even replace CNS irradiation. Particularly the latter is an important goal for management of adult ALL, since it often leads to treatment interruptions and delays of chemotherapy. The resulting reduced time-dose-intensity has a negative prognostic impact. Altogether the effects of innovative CNS prophylaxis not only on CNS relapse rates but on systemic relapse rate have to be evaluated in future trials. With all modifications, it will be essential to maintain the high efficacy of current treatment regimens for adult ALL, which generally yield CNS relapse rates below 5%.
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